Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Can Render Patients with ALL Into PCR-Negative Remission and Can be an Effective Bridge to Transplant (HCT)

(2018) Haneen Shalabi et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Posttransplant chimeric antigen receptor therapy

(2018) Melody Smith et al.   BLOOD

Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells

(2018) Jae H Park et al.   CLINICAL INFECTIOUS DISEASES

Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts

(2018) Ping-Pin Zheng et al.   DRUG DISCOVERY TODAY

Clinical use of lentiviral vectors

(2018) Michael C. Milone et al.   LEUKEMIA

Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products

(2018) Kenneth Cornetta et al.   MOLECULAR THERAPY

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

(2018) Margherita Norelli et al.   NATURE MEDICINE

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

(2018) Theodoros Giavridis et al.   NATURE MEDICINE

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abstract 1631: T cell dysfunction in pediatric cancer patients at diagnosis and after chemotherapy can limit chimeric antigen receptor potential

(2018) Rajat K. Das et al.   CANCER RESEARCH

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL

(2017) J Duell et al.   LEUKEMIA

Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

(2017) James N. Kochenderfer et al.   MOLECULAR THERAPY

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

(2017) E. Mejstríková et al.   Blood Cancer Journal

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

(2017) Juliane Gust et al.   Cancer Discovery

The why, what, and how of the new FACT standards for immune effector cells

(2017) Marcela V. Maus et al.   Journal for ImmunoTherapy of Cancer

How I vaccinate blood and marrow transplant recipients

(2016) P. A. Carpenter et al.   BLOOD

Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy

(2016) V. G. Bhoj et al.   BLOOD

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

(2016) Partow Kebriaei et al.   JOURNAL OF CLINICAL INVESTIGATION

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

(2016) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toxicity and management in CAR T-cell therapy

(2016) Challice L Bonifant et al.   Molecular Therapy-Oncolytics

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia

(2015) Hanren Dai et al.   OncoImmunology

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

(2014) Lorry G. Rubin et al.   CLINICAL INFECTIOUS DISEASES

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

(2013) C. R. Y. Cruz et al.   BLOOD

CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia

(2013) Marco L. Davila et al.   PLoS One

Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

(2012) J. Scholler et al.   Science Translational Medicine

Solving the Problem of γ-Retroviral Vectors Containing Long Terminal Repeats

(2011) Derek A Persons et al.   MOLECULAR THERAPY

Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial

(2009) Clifton O. Bingham et al.   ARTHRITIS AND RHEUMATISM